NVAX Can COVID vaccine be a panacea for Novavax’s (NVAX) growth needs? 5 years ago The market has been closely following the activities of leading biopharma companies for some time, looking for updates on their… Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2 6 years ago After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of… Novavax Inc. (NVAX) Q2 2020 Earnings Call Transcript 6 years ago Novavax Inc (NASDAQ: NVAX) Q2 2020 earnings call dated Aug. 10, 2020 Corporate Participants: Silvia Taylor — Senior Vice President, Investor Relations… Novavax (NVAX) tops Q2 2020 bottom line targets, misses revenue views 6 years ago Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue… Fueled by funding, Novavax (NVAX) gains ground in race for Covid-19 vaccine 6 years ago For Novavax Inc. (NASDAQ: NVAX), the new fiscal year is of great significance due to the progress it has achieved… Novavax Inc. (NASDAQ: NVAX) Q1 2020 Earnings Call Transcript 6 years ago Novavax Inc. (NVAX) Q1 2020 earnings call dated May 11, 2020 Corporate Participants: Erika Trahan — Investor Relations Stanley C. Erck — President and… Novavax (NVAX) posts wider-than-expected loss in Q4 6 years ago Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower… « Previous